CPA CPA - GeoVax Labs CFO Sec
| GOVX Stock | USD 1.42 0.08 5.33% |
Insider
CPA CPA is CFO Sec of GeoVax Labs
| Age | 62 |
| Address | 1900 Lake Park Drive, Smyrna, GA, United States, 30080 |
| Phone | (678) 384-7220 |
| Web | https://www.geovax.com |
GeoVax Labs Management Efficiency
The company has return on total asset (ROA) of (1.121) % which means that it has lost $1.121 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7602) %, meaning that it created substantial loss on money invested by shareholders. GeoVax Labs' management efficiency ratios could be used to measure how well GeoVax Labs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.64 in 2025. Return On Capital Employed is likely to rise to -3.97 in 2025. At this time, GeoVax Labs' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.7 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 779.5 K in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ian MBA | Jaguar Animal Health | 57 | |
| Mike Jenkins | iBio, Common Stock | N/A | |
| Raphael Mechoulam | 180 Life Sciences | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 63 | |
| Vijay Tammara | Ocugen Inc | 64 | |
| Chester III | Revelation Biosciences | 45 | |
| Melissa Berquist | iBio, Common Stock | N/A | |
| James Rolke | Revelation Biosciences | 56 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
| John Cini | Sonnet Biotherapeutics Holdings | 72 | |
| Carol Lizak | Jaguar Animal Health | 60 | |
| Robert Lutz | iBio, Common Stock | 55 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| FACP MD | Ocugen Inc | N/A | |
| David Sesin | Jaguar Animal Health | N/A | |
| Thomas III | iBio, Common Stock | 57 | |
| Pravin Chaturvedi | Jaguar Animal Health | 62 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Michael Shine | Ocugen Inc | N/A | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
Management Performance
| Return On Equity | -2.76 | ||||
| Return On Asset | -1.12 |
GeoVax Labs Leadership Team
Elected by the shareholders, the GeoVax Labs' board of directors comprises two types of representatives: GeoVax Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeoVax. The board's role is to monitor GeoVax Labs' management team and ensure that shareholders' interests are well served. GeoVax Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeoVax Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Sec | ||
| Mark Newman, Chief Officer | ||
| Jeffrey Welch, Head Operations | ||
| MD FACOG, Special Directors | ||
| Mark CPA, CFO Secretary | ||
| Harriet Robinson, Co-Founder, Chief Scientific Officer and Director | ||
| John Sharkey, Vice Development | ||
| Thomas OBrien, Vice Compliance | ||
| David Dodd, Independent Chairman of the Board | ||
| John Niles, Head Operations | ||
| McKee MD, Chief Officer |
GeoVax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GeoVax Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.76 | ||||
| Return On Asset | -1.12 | ||||
| Operating Margin | (2.10) % | ||||
| Current Valuation | 11.98 M | ||||
| Shares Outstanding | 9.44 M | ||||
| Shares Owned By Insiders | 0.47 % | ||||
| Shares Owned By Institutions | 8.32 % | ||||
| Number Of Shares Shorted | 762.64 K | ||||
| Price To Earning | (1.25) X | ||||
| Price To Book | 1.58 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for GeoVax Stock Analysis
When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.